



Director/PDMR Shareholding

January 8, 2019 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")

Notification of transactions by persons discharging managerial responsibilities

1.		Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")	
a)	Name	Flemming Ornskov	
2.	Reason for the notificati	Reason for the notification	
a)	Position / status	Chief Executive Officer - PDMR	
b)	Initial notification / amendment	Initial notification	
3.	Details of the issuer, em auction monitor	ission allowance participant, aud	ction platform, auctioneer or
a)	Name	Shire plc	
b)	LEI	54930005LQRLI2UXRQ59	
4.	each type of transaction been conducted	n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	ice where transactions have
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs") ISIN: US82481R1068	
	Identification code		
b)	Nature of the transaction	Exercise of Stock Appreciation Rights ("SARs") awarded under the Shire Portfolio Share Plan ("PSP") on February 28, 2013. In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.	
,		Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$95.04	45,601
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
5.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Exercise of Stock Appreciation R the Shire Portfolio Share Plan ("F accordance with the rules of the I	PSP") on May 2, 2013. In

		Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.	
۵)	Drice (a) and values a(a)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$91.59	18,984
	Aggregated information	N/A (single transaction)	
d)	- Aggregated volume - Price		
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
6.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Exercise of Stock Appreciation Rights ("SARs") awarded under the Shire Portfolio Share Plan ("PSP") on February 28, 2014. In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.	
c)		Price(s)	Volume(s)
C)	Price(s) and volume(s)	\$168.54	34,174
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
7.		n(s): section to be repeated for (i; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Voluntary cancellation of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 on April 30, 2015, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
\cup_{j}	i iloc(s) and volume(s)	\$7.69	10,031

d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
8.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	normal vesting date resulting for the governing the acquisition (ii) applicable performance of level of 100%; (iii) exercise of the SARs is to amount per ADS of \$173	an 2015 ("LTIP") on February rules of the LTIP and the Co- ne Company and Takeda
-\		Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$161.42	43,329
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
9.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	nares ("ADSs")
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Vesting of Performance Stock Units ("PSUs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on February 26, 2016. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) applicable performance conditions were achieved at a level of 100%;	
		(ii) applicable performance co	nditions were achieved

d) e)	Aggregated information - Aggregated volume - Price Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
10.		n(s): section to be repeated for (i) each type of instrument; (ii); (iii) each date; and (iv) each place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	nares ("ADSs")
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 11, 2016. In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting; (iii) vesting of the RSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.	
	Price(s) and volume(s)	Price(s)	Volume(s)
c)	, - ,	\$0	4,313
c)	, , , , ,	·	4,313
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	4,313
	Aggregated information - Aggregated volume	·	4,313
d)	Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction	N/A (single transaction) January 3, 2019 N/A	
d) e)	Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Details of the transaction	N/A (single transaction) January 3, 2019) each type of instrument; (ii)
d) e) f)	Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Details of the transaction each type of transaction	N/A (single transaction) January 3, 2019 N/A n(s): section to be repeated for (in the content of the content) each type of instrument; (ii) ice where transactions have

		awarded under the Shire Long Term Incentive Plan 2015 on February 28, 2017, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018. The number of SARs outstanding prior to cancellation was reduced to reflect the the achievement of applicable performance conditions at a level of 87%.	
->	Drieg (a) and column (a)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$5.69	26,566
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
12.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Vesting of Performance Stock Units ("PSUs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on February 28, 2017. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date and the achievement of applicable performance conditions at a level of 87%; (iii) the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting; (iv) vesting of the PSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
	.,	\$0	13,441
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
13.		Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have	

	been conducted		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	nares ("ADSs")
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 10, 2017. In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of RSUs vesting was increased by an amount	
		in respect of the vesting R date of vesting; (iii) vesting of the RSUs is to be	dividends paid by the Company SUs from the award date to the se satisfied in cash in an amount f any necessary deductions for
		tax and social security con	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
0)	Trice(3) and volume(3)	\$0	3,765
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
14.		n(s): section to be repeated for (i) each type of instrument; (ii) ; (iii) each date; and (iv) each place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	nares ("ADSs")
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 9, 2018. In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;	
	(ii) the number of RSUs vesting was increased equivalent to the value of dividends paid by in respect of the vesting RSUs from the awa date of vesting; (iii) vesting of the RSUs is to be satisfied in cash per ADS of \$173.17, net of any necessary description.		ng was increased by an amount dividends paid by the Company SUs from the award date to the se satisfied in cash in an amount f any necessary deductions for
		tax and social security con Price(s)	tributions. Volume(s)
c)	Price(s) and volume(s)	\$0	3,512
		ΨΟ	5,512

d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
15.		n(s): section to be repeated for (i) each type of instrument; (ii) gilli) each date; and (iv) each place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Vesting of Performance Stock Units ("PSUs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on May 1, 2018. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date; (iii) applicable performance conditions were achieved at a level of 100%; (iv) the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting; (v) vesting of the PSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
	2 2 (2)	\$0	14,941
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")	
a)	Name	Thomas Dittrich
2.	Reason for the notification	
a)	Position / status	Chief Financial Officer - PDMR
b)	Initial notification / amendment	Initial notification
3.	Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor	
a)	Name Shire plc	

b)	LEI	54930005LQRLI2UXRQ59	
4.		n(s): section to be repeated for (; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pe	nce each ("Ordinary Shares")
	Identification code	ISIN: JE00B2QKY057	
		Vesting of Performance Stock Ur Shire Long Term Incentive Plan 2 2018. In accordance with the rul Operation Agreement between the Pharmaceutical Company Limite	2015 ("LTIP") on March 29, es of the LTIP and the Co- ne Company and Takeda
		normal vesting date resu Jersey's sanctioning of the	accelerated relative to the Itant of the Royal Court of ne scheme of arrangement of the Company by Takeda;
b)	Nature of the transaction		ing was reduced to reflect the ng relative to the normal vesting
		(iii) applicable performance of level of 100%;	conditions were achieved at a
		equivalent to the value o	ing was increased by an amount f dividends paid by the Company PSUs from the award date to the
		per Ordinary Share of £4	be satisfied in cash in an amount 7.12, net of any necessary ocial security contributions.
-)	Drie a (a) and making a (a)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	£0	2,544
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
5.		n(s): section to be repeated for (; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")	
	Identification code	ISIN: JE00B2QKY057	
b)	Nature of the transaction	Vesting of Performance Stock Ur Shire Long Term Incentive Plan 2 accordance with the rules of the Agreement between the Compar Company Limited ("Takeda") date	2015 ("LTIP") on May 1, 2018. In LTIP and the Co-Operation by and Takeda Pharmaceutical
<i>5)</i>	Nature of the transaction	normal vesting date resu Jersey's sanctioning of the governing the acquisition	accelerated relative to the Itant of the Royal Court of ne scheme of arrangement of the Company by Takeda;
		(ii) the number of PSUs vest	ing was reduced to reflect the

		accelerated date of vesting relative to the normal vesting date;	
		(iii) applicable performance conditions were achieved at a level of 100%;	
		 (iv) the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting; 	
		vesting of the PSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.	
٥)	Driag(a) and values (a)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	£0	16,854
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")		
a)	Name	Andy Busch	
2.	Reason for the notificati	on	
a)	Position / status	Head of Research and Development and Chief Scientific Officer - PDMR	
b)	Initial notification / amendment	Initial notification	
3.	Details of the issuer, em auction monitor	ission allowance participant, auction platform, auctioneer or	
a)	Name	Shire plc	
b)	LEI	54930005LQRLI2UXRQ59	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")	
	Identification code	ISIN: JE00B2QKY057	
b)	Nature of the transaction	ISIN: JE00B2QKY057 Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on March 1, 2018. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting dates resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of RSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting dates;	
		dates; (iii) the number of RSUs vesting was increased by an amo	

		equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the	
		date of vesting; (iv) vesting of the RSUs is to amount per Ordinary Shannecessary deductions for contributions.	
- \	D: ()	Price(s)	Volume(s)
c)	Price(s) and volume(s)	£0	7,628
	Aggregated information	N/A (single transaction)	
d)	- Aggregated volume - Price		
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
5.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")	
	Identification code	ISIN: JE00B2QKY057	
b)	Nature of the transaction	vesting dates resultant of t sanctioning of the scheme acquisition of the Compan (ii) the number of SARs vesting accelerated date of vesting date;	an 2015 ("LTIP") on March 1, es of the LTIP and the Co- le Company and Takeda d ("Takeda") dated May 8, 2018: ccelerated relative to the normal the Royal Court of Jersey's of arrangement governing the y by Takeda; ng was reduced to reflect the g relative to the normal vesting be satisfied in cash in an amount .12, net of any necessary
c)	Price(s) and volume(s)	Price(s)	Volume(s)
<u> </u>	Thoo(s) and volume(s)	£31.29	11,132
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
6.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")	
	Identification code	ISIN: JE00B2QKY057	
b)	Nature of the transaction	Vesting of Performance Stock Units ("PSUs") awarded under the	

		accorda Agreen Compa (i)	ance with the rules of the Inent between the Companing Limited ("Takeda") date vesting of the PSUs was normal vesting date resu Jersey's sanctioning of the governing the acquisition the number of PSUs vest accelerated date of vesti date; applicable performance of level of 100%; the number of PSUs vest equivalent to the value of in respect of the vesting date of vesting; vesting of the PSUs is to	2015 ("LTIP") on May 1, 2018. In LTIP and the Co-Operation by and Takeda Pharmaceutical and May 8, 2018: accelerated relative to the scheme of arrangement and the Company by Takeda; thing was reduced to reflect the ang relative to the normal vesting acconditions were achieved at a sting was increased by an amount af dividends paid by the Company PSUs from the award date to the be satisfied in cash in an amount 1.7.12, net of any necessary
			deductions for tax and so	ocial security contributions.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
-,			£0	12,584
d)	Aggregated information - Aggregated volume - Price	N/A (si	ngle transaction)	
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")		
a)	Name	Joanne Cordeiro	
2.	Reason for the notificati	on	
a)	Position / status	Chief Human Resources Officer - PDMR	
b)	Initial notification / amendment	Initial notification	
3.	Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor		
a)	Name	Shire plc	
b)	LEI	54930005LQRLI2UXRQ59	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Exercise of Stock Appreciation Rights ("SARs") awarded under the Shire Portfolio Share Plan ("PSP") on February 28, 2014. In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018, exercise of the	

		SARs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
c)	Frice(s) and volume(s)	\$168.54	772	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
5.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	nares ("ADSs")	
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Voluntary cancellation of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 on February 27, 2015, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.		
۵)	Drice (a) and values a(a)	Price(s)	Volume(s)	
c)	Price(s) and volume(s)	\$7.68	1,934	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
6.		n(s): section to be repeated for (i) each type of instrument; (ii) a; (iii) each date; and (iv) each place where transactions have		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Exercise of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on February 26, 2016. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of certain of the SARs was accelerated relative to the normal vesting dates resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) exercise of the SARs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	

		\$161.42	3,495	
	Aggregated information	N/A (single transaction)		
d)	- Aggregated volume - Price			
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
7.			l for (i) each type of instrument; (ii) ch place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Voluntary cancellation of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 on February 28, 2017, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.		
۵)	Drice(a) and value (a)	Price(s)	Volume(s)	
c)	Price(s) and volume(s)	\$5.69	3,896	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
8.			for (i) each type of instrument; (ii) ch place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Deposit	ary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068		
		Vesting of Performance Stock Units ("PSUs") awarded und Shire Long Term Incentive Plan 2015 ("LTIP") on February 2017. In accordance with the rules of the LTIP and the Co Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, (i) vesting of the PSUs was accelerated relative to the		
b)	Nature of the transaction	Jersey's sanctionin governing the acqu	e resultant of the Royal Court of g of the scheme of arrangement isition of the Company by Takeda;	
,		accelerated date of	s vesting was reduced to reflect the vesting relative to the normal vesting vement of applicable performance of 87%;	
		equivalent to the va	s vesting was increased by an amount alue of dividends paid by the Company sting PSUs from the award date to the	
		(iv) vesting of the PSUs	s is to be satisfied in cash in an amount	

		per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.		
۵)	Drice (a) and values a(a)	Price(s)	Volume(s)	
c)	Price(s) and volume(s)	\$0	346	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
9.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	nares ("ADSs")	
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on February 28, 2017. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of RSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date; (iii) the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting; (iv) vesting of the RSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.		
c)	Price(s) and volume(s)	Price(s) \$0	Volume(s) 139	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
10.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla		
a)	Description of the financial instrument, type of instrument Identification code	Shire plc American Depositary Shares ("ADSs")		
b)	Nature of the transaction	ISIN: US82481R1068 Vesting of Restricted Stock Units Shire Long Term Incentive Plan 2		

		 2017. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of RSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date; (iii) the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting; (iv) vesting of the RSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions. 		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
C)	Price(s) and volume(s)	\$0	939	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
11.		n(s): section to be repeated for (i) each type of instrument; (ii); (iii) each date; and (iv) each place where transactions have		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 9, 2018. In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of RSUs vesting was increased by an amount		
		equivalent to the value of dividends paid by the Comparin respect of the vesting RSUs from the award date to the date of vesting; (iii) vesting of the RSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
-,		\$0	825	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		

e)	Date of the transaction	January 3, 2019
f)	Place of the transaction	N/A

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")			
a)	Name	Bill Mordan		
2.	Reason for the notification	on		
a)	Position / status	General Counsel and Company S	Secretary - PDMR	
b)	Initial notification / amendment	Initial notification		
3.	Details of the issuer, em auction monitor	ission allowance participant, aud	ction platform, auctioneer or	
a)	Name	Shire plc		
b)	LEI	54930005LQRLI2UXRQ59		
4.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Exercise of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on February 12, 2016. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the SARs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) exercise of the SARs is to be satisfied in cash in an amount per ADS \$173.17, net of any necessary deductions for tax and social security contributions.		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
C)	Price(s) and volume(s)	\$154.95	6,147	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
5.		on(s): section to be repeated for (i) each type of instrument; (ii) n; (iii) each date; and (iv) each place where transactions have		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Exercise of Stock Appreciation Ri the Shire Long Term Incentive Pla 2016. In accordance with the rule	an 2015 ("LTIP") on February 26,	

		Operation Agreement between th Pharmaceutical Company Limited		
		(iii) vesting of the SARs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;		
		(iv) exercise of the SARs is to be satisfied in cash in an amount per ADS \$173.17, net of any necessary deductions for tax and social security contributions.		
- \	Disc(s) and all sec(s)	Price(s)	Volume(s)	
c)	Price(s) and volume(s)	\$161.42	9,680	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
6.	each type of transaction been conducted	n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	ace where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 11, 2016. In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of RSUs vesting was increased by an amound equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting; (iii) vesting of the RSUs is to be satisfied in cash in an		
		amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.		
۵)	Dring (a) and the last	Price(s)	Volume(s)	
c)	Price(s) and volume(s)	\$0	157	
	Aggregated information	N/A (single transaction)		
d)	- Aggregated volume			
	- Price			
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
7.		etails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) ach type of transaction; (iii) each date; and (iv) each place where transactions have een conducted		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		

	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Voluntary cancellation of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 on February 28, 2017, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
0)	r nce(s) and volume(s)	\$5.69	9,415	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
8.		n(s): section to be repeated for (; (iii) each date; and (iv) each pla		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Vesting of Performance Stock Units ("PSUs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on February 28, 2017. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date and the achievement of applicable performance conditions at a level of 87%; (iii) the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting; (iv) vesting of the PSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
,	, , , , , , , , , , , , , , , , , , , ,	\$0	5,140	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
9.		n(s): section to be repeated for (; (iii) each date; and (iv) each pla		

	been conducted			
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 10, 2017. I accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of RSUs vesting was increased by an amore equivalent to the value of dividends paid by the Company		
		in respect of the vesting date of vesting; (iii) vesting of the RSUs is to amount per ADS of \$173	RSUs from the award date to the be satisfied in cash in an 3.17, net of any necessary ocial security contributions.	
-)	Dring(a) and values a(a)	Price(s)	Volume(s)	
c)	Price(s) and volume(s)	\$0	869	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
10.		n(s): section to be repeated for (i) each type of instrument; (ii); (iii) each date; and (iv) each place where transactions have		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	nares ("ADSs")	
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 9, 2018. In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;		
		 (ii) the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting; (iii) vesting of the RSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions. 		
,	2. //	Price(s)	Volume(s)	
c)	Price(s) and volume(s)	\$0	1,039	
	1		i.	

d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
11.		n(s): section to be repeated for (i) each type of instrument; (ii); (iii) each date; and (iv) each place where transactions have		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Vesting of Performance Stock Units ("PSUs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on May 1, 2018. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date; (iii) applicable performance conditions were achieved at a level of 100%; (iv) the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting; (v) vesting of the PSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		\$0	5,060	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")	
a)	Name	Perry Sternberg
2.	Reason for the notification	
a)	Position / status	Head of US Commercial - PDMR
b)	Initial notification / amendment Initial notification	
3.	Details of the issuer, em auction monitor	ission allowance participant, auction platform, auctioneer or

a)	Name	Shire plc	
b)	LEI	54930005LQRLI2UXRQ59	
4.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Exercise of Stock Appreciation Rights ("SARs") awarded under the Shire Portfolio Share Plan ("PSP") on February 28, 2014. In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.	
c)	Price(s) and valume(s)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$168.54	1,485
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
5.		n(s): section to be repeated for (i) each type of instrument; (ii); (iii) each date; and (iv) each place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Sh	nares ("ADSs")
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Voluntary cancellation of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 on February 27, 2015, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.	
-)	Drieg (a) and red reserve	Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$7.68	5,909
	Aggregated information	N/A (single transaction)	
d)	- Aggregated volume		
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
6.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
	•		

b)	Nature of the transaction	Exercise of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on February 26, 2016. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of certain of the SARs was accelerated relative to the normal vesting dates resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) exercise of the SARs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
<u> </u>	Thoc(o) and volume(o)	\$161.42	8,896
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
7.		n(s): section to be repeated for (i) each type of instrument; (ii); (iii) each date; and (iv) each place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Voluntary cancellation of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 on February 28, 2017, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.	
-\	Disa(s) and all ma(s)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$5.69	9,511
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
8.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
b)	Nature of the transaction	Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 9, 2018. In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical	

		Company Limited ("Takeda") date	ed May 8, 2018:
		(i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;	
		 the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting; 	
		amount per ADS of \$173	be satisfied in cash in an 3.17, net of any necessary pocial security contributions.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
C)	Frice(s) and volume(s)	\$0	719
d)	Aggregated information - Aggregated volume	N/A (single transaction)	
	- Price		
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
9.		n(s): section to be repeated for (; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
	Identification code	ISIN: US82481R1068	
		Vesting of Performance Stock Ur Shire Long Term Incentive Plan 2 accordance with the rules of the I Agreement between the Compan Company Limited ("Takeda") date	2015 ("LTIP") on May 1, 2018. In LTIP and the Co-Operation by and Takeda Pharmaceutical
		Jersey's sanctioning of the	accelerated relative to the iltant of the Royal Court of ne scheme of arrangement n of the Company by Takeda;
b)	Nature of the transaction		ting was reduced to reflect the ng relative to the normal vesting
		(iii) applicable performance of level of 100%;	conditions were achieved at a
		equivalent to the value o	ting was increased by an amount f dividends paid by the Company PSUs from the award date to the
		• ,	be satisfied in cash in an amount of any necessary deductions for ontributions.
c)	Drigg(g) and values (g)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	\$0	3,979
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	

e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A	N/A	
10.		(s): section to be repeated for (i) each type of instrument; (ii) (iii) each date; and (iv) each place where transactions have		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Vesting of Restricted Stock Award ("RSA") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 10, 2017. In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSA was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) as a result of the vesting of the RSA, restrictions applying to the applicable ADSs already held will cease to apply.		
->	Drive (a) and values (a)	Price(s)	Volume(s)	
c)	Price(s) and volume(s)	\$0	530	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")	
a)	Name	Kim Stratton
2.	Reason for the notificati	on
a)	Position / status	Head of International Commercial - PDMR
b)	Initial notification / amendment	Initial notification
3.	Details of the issuer, em auction monitor	ission allowance participant, auction platform, auctioneer or
a)	Name	Shire plc
b)	LEI	54930005LQRLI2UXRQ59
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")
	Identification code	ISIN: JE00B2QKY057
b)	Nature of the transaction	Exercise of Stock Appreciation Rights ("SARs") awarded under the Shire Portfolio Share Plan ("PSP") on August 29, 2013. In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical

		Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.	
۵)	Drice (a) and values a(a)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	£24.00	9,787
	Aggregated information	N/A (single transaction)	
d)	- Aggregated volume - Price		
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
5.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pe	nce each ("Ordinary Shares")
	Identification code	ISIN: JE00B2QKY057	
b)	Nature of the transaction	Exercise of Stock Appreciation Rights ("SARs") awarded under the Shire Portfolio Share Plan ("PSP") on February 28, 2014. In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
C)	Frice(s) and volume(s)	£33.83	6,590
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
6.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")	
	Identification code	ISIN: JE00B2QKY057	
b)	Nature of the transaction	Voluntary cancellation of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 on February 27, 2015, in consideration of a cash payment from the Company per Ordinary Share subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
<i>U)</i>	r noe(s) and volume(s)	£1.65	12,623

Aggregated information - Aggregated volume - Price	N/A (single transaction)	
Date of the transaction	January 3, 2019	
Place of the transaction	N/A	
Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")	
Identification code	ISIN: JE00B2QKY057	
Nature of the transaction	Exercise of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on February 26, 2016. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of certain of the SARs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) exercise of the SARs is to be satisfied in cash in an	
	necessary deductions for contributions.	
Price(s) and volume(s)	Price(s)	Volume(s)
Thoo(o) and volume(o)	£38.50	15,086
Aggregated information - Aggregated volume	N/A (single transaction)	
	January 3, 2019	
Place of the transaction	N/A	
each type of transaction	n(s): section to be repeated for (i	
Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pe	nce each ("Ordinary Shares")
Identification code	ISIN: JE00B2QKY057	
Nature of the transaction	Vesting of Performance Stock Units ("PSUs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on February 26, 2016. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) applicable performance conditions were achieved at a level of 100%; (iii) the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company	
	- Aggregated volume - Price Date of the transaction Place of the transaction Details of the transaction each type of transaction been conducted Description of the financial instrument, type of instrument Identification code Nature of the transaction Price(s) and volume(s) Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Details of the transaction been conducted Description of the financial instrument, type of instrument Identification code	- Aggregated volume - Price Date of the transaction Place of the transaction (iii) each date; and (iv) each place of the transaction; (iii) each date; and (iv) each place of the transaction; (iii) each date; and (iv) each place of the financial instrument, type of instrument Identification code Nature of the transaction Nature of the transaction Price(s) and volume(s) Price(s) and volume - Price Date of the transaction Place of the transaction Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Place of the transaction N/A Details of the transaction Place of the transaction Shire plc Ordinary Shares of 5 per of Stock Appreciation Right the Place of Shire

		in respect of the vesting	PSUs from the award date to the
		date of vesting;	
		per Ordinary Share of £4	be satisfied in cash in an amount 7.12, net of any necessary ocial security contributions.
-\	Dring(s) and unlivers(s)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	£0	2,136
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
9.		n(s): section to be repeated for (; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pe	nce each ("Ordinary Shares")
	Identification code	ISIN: JE00B2QKY057	
b)	Nature of the transaction	normal vesting date resu Jersey's sanctioning of th governing the acquisition (ii) the number of RSUs vest equivalent to the value of in respect of the vesting date of vesting; (iii) vesting of the RSUs is to amount per Ordinary Sha deductions for tax and so	2015 ("LTIP") on February 26, es of the LTIP and the Co- e Company and Takeda
c)	Price(s) and volume(s)	Price(s)	Volume(s) 748
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
10.		n(s): section to be repeated for (i ; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument Identification code	Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares") ISIN: JE00B2QKY057	
b)	Nature of the transaction	Vesting of Restricted Stock Units	
~)	. rataro or the transaction	Shire Long Term Incentive Plan 2015 ("LTIP") on August 5, 2016.	

		In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date(s) resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting; (iii) vesting of the RSUs is to be satisfied in cash in an amount per Ordinary Share £47.12, net of any necessary deductions for tax and social security contributions.	
- \		Price(s)	Volume(s)
c)	Price(s) and volume(s)	£0	3113
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
11.		n(s): section to be repeated for (i) each type of instrument; (ii) ; (iii) each date; and (iv) each place where transactions have	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pe	nce each ("Ordinary Shares")
	Identification code	ISIN: JE00B2QKY057	
b)	Identification code Nature of the transaction	Voluntary cancellation of Stock A awarded under the Shire Long Te February 28, 2017, in considerati Company per Ordinary Share subnecessary deductions for tax and accordance with the Co-Operatio Company and Takeda Pharmace May 8, 2018.	erm Incentive Plan 2015 on on of a cash payment from the oject to the SAR, net of any social security contributions, in n Agreement between the
	Nature of the transaction	Voluntary cancellation of Stock A awarded under the Shire Long Te February 28, 2017, in consideration Company per Ordinary Share subspaces and decordance with the Co-Operation Company and Takeda Pharmace	erm Incentive Plan 2015 on on of a cash payment from the oject to the SAR, net of any social security contributions, in n Agreement between the
b)		Voluntary cancellation of Stock A awarded under the Shire Long Te February 28, 2017, in consideration Company per Ordinary Share subsects and accordance with the Co-Operation Company and Takeda Pharmace May 8, 2018.	erm Incentive Plan 2015 on on of a cash payment from the oject to the SAR, net of any social security contributions, in a Agreement between the utical Company Limited dated
	Nature of the transaction	Voluntary cancellation of Stock A awarded under the Shire Long Te February 28, 2017, in consideration Company per Ordinary Share subsection for tax and accordance with the Co-Operation Company and Takeda Pharmace May 8, 2018. Price(s)	erm Incentive Plan 2015 on on of a cash payment from the oject to the SAR, net of any social security contributions, in a Agreement between the utical Company Limited dated Volume(s)
c)	Nature of the transaction Price(s) and volume(s) Aggregated information - Aggregated volume	Voluntary cancellation of Stock A awarded under the Shire Long Te February 28, 2017, in consideration Company per Ordinary Share subsection for tax and accordance with the Co-Operation Company and Takeda Pharmace May 8, 2018. Price(s) £1.52	erm Incentive Plan 2015 on on of a cash payment from the oject to the SAR, net of any social security contributions, in a Agreement between the utical Company Limited dated Volume(s)
c) d)	Nature of the transaction Price(s) and volume(s) Aggregated information - Aggregated volume - Price	Voluntary cancellation of Stock A awarded under the Shire Long Te February 28, 2017, in consideratic Company per Ordinary Share subsection of tax and accordance with the Co-Operatio Company and Takeda Pharmace May 8, 2018. Price(s) £1.52 N/A (single transaction)	erm Incentive Plan 2015 on on of a cash payment from the oject to the SAR, net of any social security contributions, in a Agreement between the utical Company Limited dated Volume(s)
c) d)	Price(s) and volume(s) Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Details of the transaction each type of transaction	Voluntary cancellation of Stock A awarded under the Shire Long Te February 28, 2017, in considerating Company per Ordinary Share substances and accordance with the Co-Operation Company and Takeda Pharmace May 8, 2018. Price(s) £1.52 N/A (single transaction) January 3, 2019	erm Incentive Plan 2015 on on of a cash payment from the oject to the SAR, net of any social security contributions, in a Agreement between the utical Company Limited dated Volume(s) 26,587
c) d) e) f)	Nature of the transaction Price(s) and volume(s) Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Details of the transactio	Voluntary cancellation of Stock A awarded under the Shire Long Te February 28, 2017, in considerating Company per Ordinary Share substances and accordance with the Co-Operation Company and Takeda Pharmace May 8, 2018. Price(s) £1.52 N/A (single transaction) January 3, 2019 N/A n(s): section to be repeated for (in the Shire Long Teacher)	erm Incentive Plan 2015 on on of a cash payment from the oject to the SAR, net of any social security contributions, in a Agreement between the utical Company Limited dated Volume(s) 26,587

		2017. In accordance with the rules of the LTIP and the Co- Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018:	
		 vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; 	
		 (ii) the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date and the achievement of applicable performance conditions at a level of 87%; (iii) the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting; (iv) vesting of the PSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions. 	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
<i>U</i>)	i noc(s) and volume(s)	£0	14,518
	Aggregated information	N/A (single transaction)	
d)	- Aggregated volume		
	- Price		
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
13.		n(s): section to be repeated for (; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")	
	Identification code	ISIN: JE00B2QKY057	
		Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 10, 2017. In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018:	
b)	Nature of the transaction	vesting date resultant of th	of arrangement governing the
		equivalent to the value of	ng was increased by an amount dividends paid by the Company SUs from the award date to the
		(iii) vesting, vesting of the RSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.	
۵)	Drice(e) and values (a)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	£0	2,957
	1	ı	l .

d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
14.		n(s): section to be repeated for (; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pe	ence each ("Ordinary Shares")
	Identification code	ISIN: JE00B2QKY057	
b)	Nature of the transaction	vesting date(s) resultant or sanctioning of the scheme acquisition of the Compan (ii) the number of RSUs vesting	("DBP") on March 9, 2018. In DBP and the Co-Operation by and Takeda Pharmaceutical ed May 8, 2018: accelerated relative to the normal of the Royal Court of Jersey's of arrangement governing the
		in respect of the vesting R date of vesting;	SUs from the award date to the pe satisfied in cash in an amount .12, net of any necessary
-)	District and section	Price(s)	Volume(s)
c)	Price(s) and volume(s)	£0	3,915
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	
15.		n(s): section to be repeated for (; (iii) each date; and (iv) each pla	
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pe	ence each ("Ordinary Shares")
	Identification code	ISIN: JE00B2QKY057	
b)	Nature of the transaction	(i) vesting of the PSUs was accelerated relative to the norm	
		vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;	
		(ii) the number of PSUs vestir	ng was reduced to reflect the

		accelerated date of vesting relative to the normal vesting date;	
		(iii) applicable performance conditions were achieved at a level of 100%;	
		 (iv) the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting; (v) vesting of the PSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions. 	
-\	Dries (s) and values o(s)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	£0	13,488
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")			
a)	Name	Matt Walker		
2.	Reason for the notificati	ion		
a)	Position / status	Head of Technical Operations - PDMR		
b)	Initial notification / amendment	Initial notification		
3.	Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor			
a)	Name	Shire plc		
b)	LEI	54930005LQRLI2UXRQ59		
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Voluntary cancellation of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 on May 2, 2016, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		\$5.78	5,162	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		

e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
5.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Voluntary cancellation of Stock Appreciation Rights ("SARs") awarded under the Shire Long Term Incentive Plan 2015 on February 28, 2017, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.		
c)	Drice(s) and valume(s)	Price(s)	Volume(s)	
c)	Price(s) and volume(s)	\$5.69	8,179	
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)		
e)	Date of the transaction	January 3, 2019		
f)	Place of the transaction	N/A		
6.		saction(s): section to be repeated for (i) each type of instrument; (ii) action; (iii) each date; and (iv) each place where transactions have		
a)	Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")		
	Identification code	ISIN: US82481R1068		
b)	Nature of the transaction	Vesting of Performance Stock Units ("PSUs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on February 28, 2017. In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date and the achievement of applicable performance		
		conditions at a level of 87%; (iii) the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting; (iv) vesting of the PSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for		
		tax and social security co		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		\$0	4,466	

	Shire Deferred Bonus Plan 2015 accordance with the rules of the Dagreement between the Company	nares ("ADSs") ("RSUs") awarded under the ("DBP") on March 10, 2017. In
Details of the transaction each type of transaction been conducted Description of the financial instrument, type of instrument	n(s): section to be repeated for (i; (iii) each date; and (iv) each plate is shire plc American Depositary Shire plc American Depositary Shire US82481R1068 Vesting of Restricted Stock Units Shire Deferred Bonus Plan 2015 accordance with the rules of the Eagreement between the Company	nares ("ADSs") ("RSUs") awarded under the ("DBP") on March 10, 2017. In
each type of transaction been conducted Description of the financial instrument, type of instrument	Shire plc American Depositary Shire plc American Depositary Shire plc American Depositary Shire US82481R1068 Vesting of Restricted Stock Units Shire Deferred Bonus Plan 2015 accordance with the rules of the Eagreement between the Company	nares ("ADSs") ("RSUs") awarded under the ("DBP") on March 10, 2017. In
financial instrument, type of instrument	ISIN: US82481R1068 Vesting of Restricted Stock Units Shire Deferred Bonus Plan 2015 accordance with the rules of the D Agreement between the Company	("RSUs") awarded under the ("DBP") on March 10, 2017. In
Identification code	Vesting of Restricted Stock Units Shire Deferred Bonus Plan 2015 accordance with the rules of the D Agreement between the Company	("DBP") on March 10, 2017. In
	Shire Deferred Bonus Plan 2015 accordance with the rules of the Dagreement between the Company	("DBP") on March 10, 2017. In
Nature of the transaction	Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 10, 2017. In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda; (ii) the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting; (iii) vesting of the RSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.	
Price(s) and volume(s)	Price(s)	Volume(s)
	\$0	418
Aggregated information - Aggregated volume - Price	N/A (single transaction)	
Date of the transaction	January 3, 2019	
Place of the transaction	N/A	
	the transaction(s): section to be repeated for (i) each type of instrument; (ii) of transaction; (iii) each date; and (iv) each place where transactions have	
Description of the financial instrument, type of instrument	Shire plc American Depositary Shares ("ADSs")	
Identification code	ISIN: US82481R1068	
Nature of the transaction	Vesting of Restricted Stock Units ("RSUs") awarded under the Shire Deferred Bonus Plan 2015 ("DBP") on March 9, 2018. In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited ("Takeda") dated May 8, 2018: (i) vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey's sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;	
	Price(s) and volume(s) Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Details of the transaction each type of transaction been conducted Description of the financial instrument, type of instrument Identification code	Nature of the transaction Price(s) and volume(s) Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Peach type of transaction; (iii) each date; and (iv) each place of instrument, type of instrument ldentification code Nature of the transaction Nature of the vesting of the RSUs was normal vesting date resultation N

		equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting; (iii) vesting of the RSUs is to be satisfied in cash in an amount per ADS of \$173.17, net of any necessary deductions for tax and social security contributions.	
٥)	Price(s) and volume(s)	Price(s)	Volume(s)
c)		\$0	924
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	January 3, 2019	
f)	Place of the transaction	N/A	

For further information please contact:

Investor Relations

Christoph Brackmann christoph.brackmann@shire.com +41 41 288 41 29
Sun Kim sun.kim@shire.com +1 617 588 8175
Scott Burrows scott.burrows@shire.com +41 41 288 4195

Media

Katie Joyce kjoyce@shire.com +1 781 482 2779

NOTES TO EDITORS

Shire is now part of Takeda.

www.takeda.com

www.shire.com